ACRS – Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc.ACRS
$4.30Name : Aclaris Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $600,553,856.00
EPSttm : -0.56
Aclaris Therapeutics, Inc.
$4.30
1.38%$0.06
ACRS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
6.68
Margin Of Safety %
Put/Call OI Ratio
0.53
EPS Next Q Diff
-1.04
EPS Last/This Y
-0.12
EPS This/Next Y
-0.17
Price
4.3
Target Price
10.45
Analyst Recom
1.17
Performance Q
17.17
Upside
-269.3%
Beta
0.81
Ticker: ACRS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | ACRS | 4.96 | 0.36 | 0.01 | 10809 |
| 2026-05-12 | ACRS | 4.88 | 0.36 | 0.04 | 10796 |
| 2026-05-13 | ACRS | 5.09 | 0.36 | 0.00 | 10784 |
| 2026-05-14 | ACRS | 4.8 | 0.36 | 0.19 | 10785 |
| 2026-05-15 | ACRS | 4.53 | 0.36 | 0.02 | 10782 |
| 2026-05-18 | ACRS | 4.41 | 0.36 | 0.12 | 8657 |
| 2026-05-19 | ACRS | 4.46 | 0.37 | 0.03 | 8634 |
| 2026-05-20 | ACRS | 4.53 | 0.37 | 0.46 | 8735 |
| 2026-05-21 | ACRS | 4.54 | 0.37 | 0.00 | 8748 |
| 2026-05-22 | ACRS | 4.53 | 0.36 | 6.12 | 8811 |
| 2026-05-26 | ACRS | 4.51 | 0.39 | 2.44 | 9045 |
| 2026-05-27 | ACRS | 4.59 | 0.41 | 0.04 | 9142 |
| 2026-05-28 | ACRS | 4.57 | 0.41 | 0.25 | 9200 |
| 2026-05-29 | ACRS | 4.55 | 0.48 | 0.00 | 9706 |
| 2026-06-02 | ACRS | 4.64 | 0.58 | 0.13 | 10473 |
| 2026-06-03 | ACRS | 4.41 | 0.59 | 0.13 | 10424 |
| 2026-06-04 | ACRS | 4.72 | 0.59 | 0.00 | 10458 |
| 2026-06-05 | ACRS | 4.37 | 0.54 | 0.07 | 11078 |
| 2026-06-08 | ACRS | 4.37 | 0.53 | 0.00 | 11136 |
| 2026-06-09 | ACRS | 4.3 | 0.53 | 0.19 | 11192 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | ACRS | 4.96 | -29.8 | - | -0.65 |
| 2026-05-12 | ACRS | 4.88 | -29.8 | - | -0.66 |
| 2026-05-13 | ACRS | 5.09 | -29.8 | - | -0.66 |
| 2026-05-14 | ACRS | 4.80 | -29.8 | - | -0.66 |
| 2026-05-15 | ACRS | 4.53 | -29.8 | - | -0.66 |
| 2026-05-18 | ACRS | 4.41 | -28.2 | - | -0.66 |
| 2026-05-19 | ACRS | 4.46 | -28.2 | - | -0.66 |
| 2026-05-20 | ACRS | 4.53 | -26.9 | - | -0.64 |
| 2026-05-21 | ACRS | 4.55 | -26.9 | - | -0.64 |
| 2026-05-22 | ACRS | 4.53 | -22.0 | - | -0.64 |
| 2026-05-26 | ACRS | 4.51 | -22.0 | - | -0.64 |
| 2026-05-27 | ACRS | 4.59 | -22.0 | - | -0.64 |
| 2026-05-28 | ACRS | 4.57 | -22.0 | - | -0.64 |
| 2026-05-29 | ACRS | 4.55 | -22.0 | - | -0.64 |
| 2026-06-01 | ACRS | 4.33 | -22.0 | - | -0.64 |
| 2026-06-02 | ACRS | 4.64 | -22.0 | - | -0.64 |
| 2026-06-03 | ACRS | 4.41 | -22.0 | - | -0.64 |
| 2026-06-04 | ACRS | 4.71 | -22.0 | - | -0.64 |
| 2026-06-05 | ACRS | 4.37 | -22.0 | - | -0.64 |
| 2026-06-08 | ACRS | 4.37 | -23.1 | - | -0.66 |
| 2026-06-09 | ACRS | 4.30 | -23.1 | - | -0.66 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | ACRS | -1.59 | -2.58 | 5.84 |
| 2026-05-12 | ACRS | -1.59 | -2.58 | 6.52 |
| 2026-05-13 | ACRS | -1.58 | -2.58 | 6.52 |
| 2026-05-14 | ACRS | -1.58 | -2.58 | 6.52 |
| 2026-05-15 | ACRS | -1.58 | -2.58 | 6.52 |
| 2026-05-18 | ACRS | -1.58 | -4.56 | 6.34 |
| 2026-05-19 | ACRS | -1.93 | -4.56 | 6.34 |
| 2026-05-20 | ACRS | -1.93 | -4.56 | 6.34 |
| 2026-05-21 | ACRS | -1.93 | -4.56 | 6.84 |
| 2026-05-22 | ACRS | -1.22 | -4.56 | 6.84 |
| 2026-05-26 | ACRS | -1.22 | 13.61 | 7.17 |
| 2026-05-27 | ACRS | -1.00 | 13.61 | 7.17 |
| 2026-05-28 | ACRS | -1.00 | 13.61 | 6.68 |
| 2026-05-29 | ACRS | -1.00 | 13.61 | 6.68 |
| 2026-06-02 | ACRS | -1.00 | 12.97 | 6.68 |
| 2026-06-03 | ACRS | -1.00 | 12.97 | 6.68 |
| 2026-06-04 | ACRS | -1.00 | 12.97 | 6.68 |
| 2026-06-05 | ACRS | -1.00 | 12.97 | 6.68 |
| 2026-06-08 | ACRS | -1.00 | 12.96 | 6.68 |
| 2026-06-09 | ACRS | -1.00 | 12.96 | 6.68 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.87
Avg. EPS Est. Current Quarter
-0.16
Avg. EPS Est. Next Quarter
-0.17
Insider Transactions
-1
Institutional Transactions
12.96
Beta
0.81
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
26
Growth Score
23
Sentiment Score
79
Actual DrawDown %
78.5
Max Drawdown 5-Year %
-96.7
Target Price
10.45
P/E
Forward P/E
PEG
P/S
71.75
P/B
4.18
P/Free Cash Flow
EPS
-0.56
Average EPS Est. Cur. Y
-0.66
EPS Next Y. (Est.)
-0.83
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-832.58
Relative Volume
0.58
Return on Equity vs Sector %
-76
Return on Equity vs Industry %
-59.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
◆
ACRS
Healthcare
$4.30
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
45.1
Range 1M
11.3%
Sup Dist
0.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-26.2%
EPS NY
-14.6%
52W%
78.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+143% upside
Upside
+143%
Quality
26
Aclaris Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 69
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS
Latest News
—
Caricamento notizie per ACRS…
stock quote shares ACRS – Aclaris Therapeutics Inc Stock Price stock today
news today ACRS – Aclaris Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ACRS – Aclaris Therapeutics Inc yahoo finance google finance
stock history ACRS – Aclaris Therapeutics Inc invest stock market
stock prices ACRS premarket after hours
ticker ACRS fair value insiders trading